Facebook Instagram Pinterest Reddit Tumblr Twitter Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 202

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human Psyche

Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Psychedelics, and Couples Therapy

Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola

The Psychedelic Practitioner Issue 3: Dosing

MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent...

Psychedelics and Substance Use Disorder: 4000 BCE to Present Day

Psyched Wellness Announces Path to Market for AME-1-derived Products in the...

COMPASS Pathways announces changes in Executive Team

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial...

atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with...

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and...

Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office...

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support...

Editor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity

1...201202203...308Page 202 of 308

EDITOR PICKS

Ketamine Assisted Psychotherapy for Couples

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human...

Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Psychedelics, and Couples...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr Twitter Youtube
    ©